Basics Celldex Therapeutics, Inc. Celldex Therapeutics Inc is a biopharmaceutical company. The company is engaged in the development and commercialization of immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. IPO Date: March 26, 1990 Sector: Healthcare Industry: Biotech Market Cap: $1.75B Activated in VL: True Average Daily Range Avg Daily Range: $0.43 | 3.04% Avg Daily Range (30 D): $0.62 | 2.30% Avg Daily Range (90 D): $0.57 | 2.20% Institutional Daily Volume Avg Daily Volume: 1.09M Avg Daily Volume (30 D): .64M Avg Daily Volume (90 D): .76M Trade Size Avg Trade Size (Sh.): 157 Avg Trade Size (Sh.) (30 D): 54 Avg Trade Size (Sh.) (90 D): 63 Institutional Trades Total Inst.Trades: 4,689 Avg Inst. Trade: $2.1M Avg Inst. Trade (30 D): $2.47M Avg Inst. Trade (90 D): $2.33M Avg Inst. Trade Volume: .05M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $2.86M Avg Closing Trade (30 D): $3.53M Avg Closing Trade (90 D): $2.95M Avg Closing Volume: 78.06K     News Aug 27, 2025 @ 8:50 AM Chronic Inducible Urticaria (CIndU) Market Researc... Source: Researchandmarkets.Com Jun 14, 2025 @ 2:48 PM Celldex Presents Data Demonstrating Profound Long ... Source: N/A Mar 3, 2025 @ 1:01 PM Celldex Therapeutics Presents Positive Preclinical... Source: N/A Mar 1, 2025 @ 5:45 PM Celldex Therapeutics Presents Positive Results fro... Source: N/A Feb 20, 2025 @ 6:00 PM Chronic Spontaneous Urticaria Market to Register I... Source: Delveinsight Financials   TTM Q3 2025 Q2 2025 Basic EPS $-3.38 $-1.01 $-.85 Diluted EPS $-3.38 $-1.01 $-.85 Revenue $ 2.6M $ M $ .73M Gross Profit $ $ $ Net Income / Loss $ -224.53M $ -67.04M $ -56.6M Operating Income / Loss $ -256.24M $ -73.62M $ -63.86M Cost of Revenue $ $ $ Net Cash Flow $ -.36M $ 12.99M $ 5.91M PE Ratio     Splits Feb 11, 2019:   1:15 Mar 10, 2008:   1:12 Mar 07, 2008:   1:12